Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE stock logo
BNTX
BioNTech
$92.72
+0.5%
$90.54
$85.21
$125.83
$22.04B0.25601,360 shs663,327 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$149.27
-0.4%
$154.19
$143.13
$175.97
$359.25B0.558.67 million shs6.53 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.81
+0.4%
$26.88
$25.20
$40.37
$157.48B0.6341.90 million shs60.57 million shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE stock logo
BNTX
BioNTech
0.00%+6.32%+3.09%+0.08%-15.80%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.00%+2.14%-2.11%-4.69%-8.35%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+9.49%+4.35%+3.27%-27.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNTech SE stock logo
BNTX
BioNTech
2.8934 of 5 stars
4.22.00.00.01.30.81.9
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9046 of 5 stars
3.23.04.23.93.02.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9804 of 5 stars
4.23.04.24.83.71.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE stock logo
BNTX
BioNTech
2.30
Hold$120.4029.85% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8617.81% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.45% Upside

Current Analyst Ratings

Latest JNJ, PFE, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$107.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/27/2024
BioNTech SE stock logo
BNTX
BioNTech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$110.00 ➝ $101.00
(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE stock logo
BNTX
BioNTech
$4.13B5.33$5.10 per share18.19$92.17 per share1.01
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.22$13.61 per share10.97$29.09 per share5.13
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.69$2.99 per share9.31$15.81 per share1.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE stock logo
BNTX
BioNTech
$1.01B$4.1222.50N/AN/A24.26%4.60%4.12%5/6/2024 (Confirmed)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.3113.662.4745.26%36.70%15.07%7/18/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.261.18-0.56%8.58%3.70%8/6/2024 (Estimated)

Latest JNJ, PFE, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
BioNTech SE stock logo
BNTX
BioNTech
-$0.4460N/A+$0.4460N/AN/AN/A  
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
3/20/2024Q4 2023
BioNTech SE stock logo
BNTX
BioNTech
$2.64$2.05-$0.59$2.05$2.04 billion$1.59 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.19%+5.70%29.68%63 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.04%+2.57%N/A 15 Years

Latest JNJ, PFE, and BNTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE stock logo
BNTX
BioNTech
0.01
9.43
9.26
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.36
1.17
0.91
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE stock logo
BNTX
BioNTech
6,133237.73 million192.08 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

JNJ, PFE, and BNTX Headlines

SourceHeadline
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming DividendDo These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
finance.yahoo.com - May 4 at 6:18 PM
Ellerson Group Inc. ADV Buys 119,262 Shares of Pfizer Inc. (NYSE:PFE)Ellerson Group Inc. ADV Buys 119,262 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 4 at 3:55 PM
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
fool.com - May 4 at 5:17 AM
FY2025 Earnings Estimate for Pfizer Inc. Issued By Leerink Partnrs (NYSE:PFE)FY2025 Earnings Estimate for Pfizer Inc. Issued By Leerink Partnrs (NYSE:PFE)
americanbankingnews.com - May 4 at 4:38 AM
Pfizer Inc. (PFE) Q1 2024 Earnings Call TranscriptPfizer Inc. (PFE) Q1 2024 Earnings Call Transcript
msn.com - May 3 at 11:19 PM
Buy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost SavingsBuy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost Savings
markets.businessinsider.com - May 3 at 11:19 PM
Pfizer (NYSE:PFE) Stock Price Down 0.3%Pfizer (NYSE:PFE) Stock Price Down 0.3%
marketbeat.com - May 3 at 9:55 PM
Amgens peek at its GLP-1 drug trial results heightens competition in obesity marketAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
finance.yahoo.com - May 3 at 6:19 PM
Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?
stocknews.com - May 3 at 1:17 PM
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With ExpectationsPfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
msn.com - May 3 at 1:16 PM
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJs New Plan to Resolve Talc ClaimsPharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
finance.yahoo.com - May 3 at 1:16 PM
Vanguard Health Care Funds Strategic Moves in Q1 2024: A Focus on Pfizer IncVanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
finance.yahoo.com - May 3 at 1:16 PM
Pfizer Inc. (NYSE:PFE) to Post FY2025 Earnings of $2.93 Per Share, Leerink Partnrs ForecastsPfizer Inc. (NYSE:PFE) to Post FY2025 Earnings of $2.93 Per Share, Leerink Partnrs Forecasts
marketbeat.com - May 3 at 12:53 PM
Heres Why Pfizer (PFE) is a Strong Momentum StockHere's Why Pfizer (PFE) is a Strong Momentum Stock
zacks.com - May 3 at 10:56 AM
Great Valley Advisor Group Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)Great Valley Advisor Group Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 9:14 AM
NHS to provide Pfizer’s Voxelotor to treat sickle cell diseaseNHS to provide Pfizer’s Voxelotor to treat sickle cell disease
pharmaceutical-technology.com - May 3 at 8:16 AM
Q1 2024 Cardiff Oncology Inc Earnings CallQ1 2024 Cardiff Oncology Inc Earnings Call
finance.yahoo.com - May 3 at 8:16 AM
3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market
investorplace.com - May 3 at 7:00 AM
Pfizer (NYSE:PFE) Shares Up 1.8% on Earnings BeatPfizer (NYSE:PFE) Shares Up 1.8% on Earnings Beat
americanbankingnews.com - May 3 at 2:12 AM
Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 12:41 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
msn.com - May 2 at 9:58 PM
Pfizer Prospects Garner Mixed Sentiment From Analysts: Finally, The Pivot Investors Have Been Waiting ForPfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
markets.businessinsider.com - May 2 at 9:58 PM
Pfizer (NYSE:PFE) Announces Quarterly  Earnings ResultsPfizer (NYSE:PFE) Announces Quarterly Earnings Results
marketbeat.com - May 2 at 4:04 PM
Pfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected EarningsPfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected Earnings
marketbeat.com - May 2 at 2:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BioNTech logo

BioNTech

NASDAQ:BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.